Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction

J. M. Wraight, A. D. Smith, J. O. Cowan, E. M. Flannery, G. P. Herbison, D. R. Taylor (Dunedin, New Zealand)

Source: Annual Congress 2002 - Asthma and COPD: pharmacology
Session: Asthma and COPD: pharmacology
Session type: Thematic Poster Session
Number: 752
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. M. Wraight, A. D. Smith, J. O. Cowan, E. M. Flannery, G. P. Herbison, D. R. Taylor (Dunedin, New Zealand). Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction. Eur Respir J 2002; 20: Suppl. 38, 752

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020


First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Nighttime short-acting beta-agonist (SABA) in asthma and COPD
Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Year: 2019

Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019



Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003

Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol
Source: International Congress 2019 – Airway physiology
Year: 2019

Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells
Source: Eur Respir J 2003; 22: Suppl. 45, 35s
Year: 2003

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma
Source: Eur Respir J 2002; 20: 1080-1087
Year: 2002



Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009

Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Source: Eur Respir J 2001; 17: 368-373
Year: 2001



Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
Source: Eur Respir J 2007; 30: 653-661
Year: 2007



Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001

COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level
Source: International Congress 2015 – COPD: notable points
Year: 2015


Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


Inhaled corticosteroids and growth of airway function in asthmatic children
Source: Eur Respir J 2004; 23: 861-868
Year: 2004



Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017

Comparison of long acting β 2-agonist inhalers for treatment of exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2003; 22: Suppl. 45, 312s
Year: 2003

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006



COPD and airway responsiveness to beta-agonists
Source: Annual Congress 2007 - Airway regulation, provocation and monitoring - III
Year: 2007